Novartis Ag (NVS) Selling, General & Administrative (2009 - 2026)
Powered by 
Analysis
Novartis Ag (NVS) Selling, General & Administrative (2009 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | SG&A (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 6.43 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | 3.63 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | 2.90 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | -3.24 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | 3.41 Bn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | 1.83 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | -2.87 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | 110.21 Mn |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 593.21 Mn |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | 351.74 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3.24 Bn |
| Mar 31, 2026 | -3.14 Bn |
| Dec 31, 2025 | -6.50 Bn |
| Sep 30, 2025 | -3.31 Bn |
| Jun 30, 2025 | -3.44 Bn |
| Mar 31, 2025 | -3.06 Bn |
| Dec 31, 2024 | -9.07 Bn |
| Sep 30, 2024 | -3.13 Bn |
| Jun 30, 2024 | -3.09 Bn |
| Mar 31, 2024 | -2.84 Bn |
| Dec 31, 2023 | -9.07 Bn |
| Sep 30, 2023 | -3.09 Bn |
| Jun 30, 2023 | -3.09 Bn |
| Mar 31, 2023 | -2.89 Bn |
| Dec 31, 2022 | -9.01 Bn |
| Sep 30, 2022 | -2.94 Bn |
| Jun 30, 2022 | -3.58 Bn |
| Mar 31, 2022 | -3.51 Bn |
| Dec 31, 2021 | -7.28 Bn |
| Sep 30, 2021 | -3.62 Bn |